TSH Biopharm Corporation Limited (TPEX:8432)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
48.25
-0.40 (-0.82%)
Jun 18, 2025, 1:30 PM CST

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Cardiovascular and Gastrointestinal Drugs
565.24M
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular and Gastrointestinal Drugs Growth
13.66%
Log In
Log In
Log In
Log In
Upgrade
Reinvestment
550.48M
Log In
Log In
Log In
Log In
Upgrade
Reinvestment Growth
75.53%
Log In
Log In
Log In
Log In
Upgrade
Lozenges
-
Log In
Log In
Log In
Log In
Upgrade
Lozenges Growth
-
Log In
Log In
Log In
Log In
Upgrade
Testing
-
Log In
Log In
Log In
Log In
Upgrade
Testing Growth
-
Log In
Log In
Log In
Log In
Upgrade
Capsules
-
Log In
Log In
Log In
Log In
Upgrade
Capsules Growth
-
Log In
Log In
Log In
Log In
Upgrade
Service
-
Log In
Log In
Log In
Log In
Upgrade
Service Growth
-
Log In
Log In
Log In
Log In
Upgrade
Injections
-
Log In
Log In
Log In
Log In
Upgrade
Injections Growth
-
Log In
Log In
Log In
Log In
Upgrade
Sales Returns and Allowances
-
Log In
Log In
Log In
Log In
Upgrade
Sales Returns and Allowances Growth
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Taiwan
1.12B
Log In
Log In
Log In
Log In
Upgrade
Taiwan Growth
37.59%
Log In
Log In
Log In
Log In
Upgrade